-
-
-
-
-
-
-
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
-
-
-
-
-
-
-
Neurocrine to acquire Soleno Therapeutics for $2.9 billion in cash deal
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX) Announces CEO Change
-
-
-
-
-
-
-
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX), Takeda (TAK) Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
-
-
-
-
-
-
-
Pre-Open Movers 10/05: (ONVI) (CERS) (MOBL) Higher; (GSAT) (IMGN) (ECYT) Lower (more...)
-
-
-
-
-
-
-
After-Hours Stock Movers 01/05: (OGXI) (STML) (GPS) Higher; (RT) (GIII) (SUM) Lower (more...)
-
1,168,812 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

